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Worldwide, diabetes in pregnancy is associated with significant fetal and maternal morbidity and mortality. The prevalence of births complicated by pre-existing diabetes has increased by 50% in under a decade \[[@CR1]\]. There is a consensus among researchers that the Caesarean section (CS) rate is higher in women with diabetes \[[@CR2]--[@CR4]\], with the Confidential Enquiry into Maternal and Child Health (CEMACH) reporting a rate of 67.4% \[[@CR5]\]. The OR for risk of emergency CS in pregnancy complicated by a diabetic pregnancy is 3--4 \[[@CR2], [@CR6]\]. CEMACH reported that 56% of CS were emergency operations not elective ones. CS in women with diabetes in pregnancy is associated with a 2.5-fold increased risk of wound infection \[[@CR7]\], and an increased risk of thrombosis and post-partum haemorrhage \[[@CR4]\]. Despite the significant attendant morbidity associated with CS in diabetic pregnancies, the high CS rate in diabetic pregnancies is not understood.

Some authors suggest that the increased CS rate is due to the confounding factor of obesity \[[@CR8]\]; however, other analyses have found diabetes mellitus to be an independent risk for CS \[[@CR2], [@CR9], [@CR10]\]. Other putative factors are macrosomia, increased fetal distress and poor myometrial activity. Although macrosomia has been reported as a risk factor for CS in women with diabetes \[[@CR2], [@CR10]\], recent work has found that a reduction in macrosomia does not result in a concomitant reduction in CS rate \[[@CR11]--[@CR13]\]. Fetal distress is cited as a reason for emergency CS in diabetes \[[@CR6]\], and fetuses of diabetic mothers are more vulnerable at term, with increased stillbirth rate \[[@CR3], [@CR4], [@CR6], [@CR14]\].

However, although fetal distress, macrosomia and obesity contribute to the increased emergency CS rate in diabetic pregnancies, prolonged labour and failed induction of labour accounted for 51% of emergency CS \[[@CR6]\]. Therefore, poor myometrial contractility may be important. Further evidence to implicate poor myometrial contractility is that post-partum haemorrhage is six times more common in diabetic women \[[@CR4]\]. Post-partum haemorrhage may be attributed to altered oxytocin responsiveness; however, clinical conditions linked to altered smooth muscle function with diabetes in other tissues include hypertension, gastric paresis, constipation, urine retention and vas deferens dysfunction. In vitro studies have found tissue-specific alterations in contractility \[[@CR15]--[@CR20]\], thus it is difficult to predict what the effects of diabetes mellitus may be on uterine contractions. There are few data concerning the effect of diabetes in the myometrium of any species and none on Ca signalling \[[@CR21]--[@CR24]\]. In the only study on human myometrium, which involved seven women who developed gestational diabetes, an increased response to endothelin-1 was reported \[[@CR25]\], but no clinical information was presented.

Thus, the purpose of our study was to elucidate whether the contractility of human myometrium is impaired in women with pregnancies complicated by diabetes and to explore the underlying mechanisms. These data in turn will shed light on the question of whether their high CS rate may be partly explained by poor contractility.

Methods {#Sec2}
=======

**Patient details** Following ethics approval and informed consent, lower segment biopsies were taken at the time of elective CS from 40 patients with diabetes and 68 without. Hospital protocol is to perform elective CS at 39 weeks gestation for non-diabetic patients and 38 weeks for diabetic patients. Clinical and demographic data are presented in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}. None of the patients in this study were in labour or had a multiple pregnancy.Table 1Patient details: type 1 diabetes mellitus (*n* = 18)Age (years)BMI (kg/m^2^)Diabetic complicationsHbA~1c~ (range)Type of insulinParityGestational age (weeks)Birthweight (kg)Caesarean indication%mmol/mol4031.6None6.1--6.243--44Humulin; humalog1383.69Previous CS4022.3None5.9--6.441--46Humalog; lantus1383.49Maternal request2628.9Retinopathy6.4--6.646--49CSII035+22.18Maternal request2430.1Microalbuminuria7.9--8.163--65Novorapid, glargine^a^0383.34Previous CS3624.6None6.0--7.042--53Novorapid, lantus137+44.5DiabetesCSII3622.4Previous nephropathy6.5--6.848--51CSII136+44.42Maternal reason2741.9None7.9--9.763--83Humalog; lantus235+34.48Diabetes3930Retinopathy6.4--8.246--66Humalog; humulin034+02.58Previous CS/maternal request4431.2Vascular6.345Insulin336+42.72Maternal reason2922.3None5.7--6.339--45Insulin1383.26Diabetes2843Nephropathy7.1--7.554--59Novorapid, lantus335+24.37Diabetes3443.8None6.750Insulin137+14.31Previous CS3722.6Retinopathy642Novorapid, lantus332+62.48Maternal reason3825.2Hypertension6.548Novorapid, lantus336+34.115Previous CS2724.2None5.941CSII333+52.46Breech4146.2Hypertension6.143Novorapid, lantus137.53.29Previous CS3624.8Retinopathy and nephropathy531Novorapid, lantus0373.27Diabetes4036.5None5.5--6.037--42Novorapid2383.75Previous CS^a^Insulin glargine (A21Gly,B31Arg,B32Arg human insulin)Table 2Gestational diabetes mellitus (*n* = 22)Age (years)BMI (kg/m^2^)HbA~1c~ (range)Type of insulinParityGestational age (weeks)Birthweight (kg)Caesarean indication%mmol/mol2635.45.4--7.036--53Insulin: novomix1383.71Previous CS2942.56.9--7.252--55Metformin and insulin:novomix138+14.16Previous CS3040.75.1--5.632--38Metformin and insulin:lantus1383.2Previous CS3326.55.3--5.634--38Diet only1383.57Previous CS3828.95.1--5.332--34Diet only1393.57Previous CS3735.65.6--5.738--39Diet only1383.74Previous CS3329.84.4--5.825--40Diet only237+64.833827.85.4--7.036--53Diet only236+52.78Previous CS31245.132Insulin: lantus138+63.03Previous CS38387.0--9.353--78Insulins: novorapid and lantus138+14.76Previous CS3631.57.457Metformin138+33.9Previous CS3533.74.1--6.221--44Insulins: novorapid and lantus238+13.3Diabetes3519.44.2--6.522--48Diet only338+23.25Diabetes2924.85.8--6.043--42Insulins: novarapid and lantus0383.98Previous CS3021.54.5--6.826--51Insulin: novorapid137+54.15Breech3228.16.446Diet only137+14.31Previous CS2750.14.728Diet only137+54.11Previous CS3623.86.345Diet only138+32.68Breech2953.16.750Diet only1363.23Hypertension2750.78.569Novorapid, lantus137+43.23Previous CS3732.45.7--5.939--41Novorapid, lantus137+35.05Previous CS3226.25.537Novorapid2383.8Previous CSTable 3Demographics of diabetic and non-diabetic patient groupsVariableType 1 diabetes mellitusGestational diabetes mellitusNon-diabetic controlsAge (years)36 (28--39)33 (30--37)33 (24--44)BMI (kg/m^2^)29.5 (24--32)29 (26--35)27 (19--45)Gestational age (weeks)37 (35--37)38 (37--38)39 (37--40)Birthweight (kg)3.42 (2.72--4.30)3.73 (3.20--4.20)3.48 (2.69--4.48)Data are median (interquartile range) from the patient groupsAll data in all groups were from women having an elective Caesarean section, i.e. they were not in labour. Elective section before 37 weeks in non-diabetic patients was due to placenta praevia, and before 38 weeks was due to rhesus disease, maternal request, placenta praevia or unstableSee ESM Table [1](#MOESM1){ref-type="media"} for full control patient dataAll non-diabetic patients were screened initially with a detailed medical and obstetric history. If there is any factor in the history, for example previous big babies \>4.5 kg, family history of diabetes, ethnicity (Asian), then patients automatically undergo a glucose tolerance test (GTT) between 24 and 28 weeks. Furthermore, if glycosuria is \>2+ glucose detected in urine dipstix checked every 2 weeks, then this also prompts testing for GTT. Age \>35 years without any risk factors does not lead to automatic GTT screening. In our unit we employ the WHO 75 g glucose load administered to fasting patients and then check glucose readings at 1 and 2 h. By these criteria none of the patients in our control group had detectable gestational diabetes mellitus. This was a specific exclusion criterion. Other exclusion criteria were pre-eclampsia and medication likely to affect contractility.

**Force and calcium measurements** Tissue preparation and measurement of calcium were as described elsewhere \[[@CR26], [@CR27]\]. In brief, dissected muscle strips (1 × 3 mm) were incubated in the Ca^2+^-sensitive indicator Indo-1 (12.5 μmol/l), for 2--3 h at room temperature. The strips were rinsed in physiological saline (see below) and then, with one end attached to a force transducer, mounted horizontally in a small (500 μl) bath for simultaneous measurement of force and Ca signalling. Tissues were superfused (3 ml/min) with physiological saline at 35°C. For Ca^2+^ measurement the tissues were excited at 340 nm and the Indo-1 fluorescence emitted at 400 and 500 nm was recorded. The ratio of these signals (F400/500) provides a measure of \[Ca\] \[[@CR28]\]. Previous studies have shown that lower segment biopsies are a good model for studying human myometrial contractility \[[@CR29]\].

**Solutions** Physiological saline with composition (mmol/l) 154 NaCl, 5.4 KCl, 1.2 MgSO~4~, 8 glucose, 2 CaCl~2~, 11 Hepes; pH 7.4. In some experiments oxytocin (10 nmol/l) or the Ca^2+^ channel agonist BAY K-8644 (1 μmol/l) were added to the perfusate.

**Protocol and analysis** Muscle strips generating stable spontaneous contractions were exposed to 40 mmol/l KCl solution (K^+^ substituted for Na in the physiological saline) for 2 min to obtain a measure of maximal activity, which could also be used to standardise between preparations. After stable contractions were established, a control period of 60 min was obtained before the physiological solution was altered. The frequency of contractions was obtained over this control period. The last three contractions of this control period were used to determine average peak amplitude and duration at half-height. The integral of force (area under the curve, in arbitrary units \[au\]) was obtained over the last 20 min of the control period. Only one result was obtained from each patient, thus n is the number of patients. Data were obtained and analysed in a blinded fashion.

**Histology** Paraffin-embedded 5 μm sections were made from ten control and diabetic myometria, and stained with both haematoxylin and eosin (H&E) to allow measurement of muscle bundles and uterine histology. Sections were also stained with Masson's Trichrome to allow measurement of collagen deposition compared with muscle. Samples were viewed at ×40 magnification by two independent observers blinded to the origin of the samples. Muscle bundles were assessed in semi-quantitative fashion in terms of muscle bundle size, organisation and separation. To determine muscle percentage and collagen deposition, images were captured using Eclipsenet software (Nikon, Nikon UK, Kingston upon Thames, UK) from ten randomly selected regions per sample, imported into ImageJ freeware (NIH, Bethsheda, MD, USA) and analysed using colour-based thresholding \[[@CR30]\].

**Western blotting and immunohistochemistry** Proteins were extracted, quantified and separated by SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes using previously described methods \[[@CR31]\]. Membranes were probed overnight with agitation at 4°C with primary antibodies as follows: rabbit polyclonal L-type calcium channel α1C 1:200 (Alomone) or mouse monoclonal glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 1:400 (AbCam) diluted in 5% non-fat dried milk in TBS/0.1% (vol./vol.) Tween 20 (TBST) or 5% protease-free bovine serum albumin in TBST respectively. Immunoreactive sites were revealed using goat anti-rabbit or goat anti-mouse IgG conjugated to horseradish peroxidase and SuperSignal West Pico substrate (Pierce-Perbio Science, Cramlington, UK).Tissue microarrays containing formalin-fixed paraffin-embedded samples of ten diabetic and ten non-diabetic myometrial tissues were processed as described in detail elsewhere \[[@CR32]\]. Microarrays also contained rat heart and skeletal muscle as positive control tissues. Immunohistochemistry was performed as described previously \[[@CR31]\] and \[[@CR33]\] using rabbit polyclonal L-type calcium channel α1C (Alomone) antibody diluted 1:100 in TBST/1% protease-free bovine serum albumin applied overnight at 4°C. Control experiments were performed by incubating slides with non-immune rabbit serum or by omitting primary antibody, or by peptide competition of 1 μg peptide per 1 μg antibody. Image capture of immunostained sections was performed using an Olympus BX51 microscope with a PL-A662 firewire camera (PixeLINK, Ottawa, ON, Canada) using a ×20 objective. Western blot signal quantification was carried out using ImageJ for Windows and the relative band intensities corresponding to L-type calcium channel expression are expressed as a percentage of the GAPDH internal control for each sample. Blots from three repeat experiments were scanned in 128 shades of grey and thresholding was used to segment blots into objects of interest.Chemicals were from Sigma, Dorset, UK unless indicated otherwise.

**Statistics** The n numbers represent different patient biopsies and only one set of data was obtained from each biopsy. Experimental data were analysed using Mann--Whitney *U*, Wilcoxon, analysis of co-variance (ANCOVA) or Student's *t* test with significance taken at *p* \< 0.05. Results are expressed as median (first and third quartile) or mean ± SEM.

Results {#Sec3}
=======

**Patients** There were no significant differences in maternal age, BMI and birthweight between type 1 diabetic (*n* = 18), gestational diabetic (*n* = 22) and non-diabetic patients (*n* = 68; Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and electronic supplementary material \[ESM\] Table [1](#MOESM1){ref-type="media"}). Type 1 diabetic patients were delivered typically at 38 weeks in order to avoid unheralded stillbirth, or earlier if there was fetal compromise or deterioration in maternal health. However, the mean gestational age of delivery for the type 1 diabetic patient remains comparable with both the gestational diabetic group and the control group, as shown.

**Spontaneous contractility** There were significant differences in the contractions between samples from diabetic and non-diabetic patients; the contractions were smaller and shorter-lasting in diabetic patients (Fig. [1c](#Fig1){ref-type="fig"}, Table [4](#Tab4){ref-type="table"}). When normalised to high K contractions (100%) these variables, were also significantly lower in the diabetic patients, 65% (55, 82%) compared with 80% (61, 90%) in non-diabetic controls; see also Fig. [1c](#Fig1){ref-type="fig"}. The significant decreases in contractility resulted in the AUC also being significantly less in diabetic patients, 2.1 (1.1, 3.5) au, compared with non-diabetic controls, 8.7 (4.0, 14.5) au. ANCOVA was used to determine the effects of possible confounders: age, BMI, birthweight and gestational age. The decreased contractility in myometrium from diabetic patients remained significant (*p* \< 0.05).Fig. 1Spontaneous, oxytocin and high K-induced activity. Spontaneous and oxytocin-induced activity. **a** and **c** Simultaneous measurements of force and Ca (Indo-1) in myometrium from non-diabetic (**a**) and diabetic patients (**c**) during spontaneous activity. Typical records from 40 diabetic and 68 non-diabetic patients. Effects of 10 nmol/l oxytocin (**b** and **d**), typical of at least five other records for both groups. **e** Comparison of the effects of 40 mmol/l K stimulation after a spontaneous contraction in non-diabetic and diabetic myometrium, typical of 13 others. **f** and **g** Representative Indo-1 records showing the Ca signals in response to spontaneous (**f**) and high K stimulation (**g**) in samples from non-diabetic and diabetic patients. In this and subsequent samples all data were obtained on myometrium from elective CS biopsies at 35°C and superfused physiological solution containing 8 mmol/l glucoseTable 4Variables of contraction and Ca transients in diabetic and non-diabetic patientsVariableSpontaneous contractionsHigh K contractionContractionsCa signalsNon-diabetic (*n* = 68)Diabetic (*n* = 40)Non-diabetic (*n* = 15)Diabetic (*n* = 9)Non-diabetic (*n* = 14)Diabetic (*n* = 14)Frequency (contraction/h)8 (6, 12)7 (5, 13)--------Amplitude (mN)2.4 (1.2, 4.5)1.5 (0.9, 2.6)\*0.7 (0.3, 1.0)0.2 (0.1, 0.5)3 (1.3, 4.5)1.5 (0.8, 3.0)\*Duration (min)1.7 (1.1, 2.5)0.9 (0.6, 1.3)\*2.0 (1.2, 3.3)1.0 (0.8,1.7)\*2.1 (1.3, 3.6)1.2 (0.8, 1.8)\*AUC (au)8.7 (4.0, 14.5)2.1 (1.1, 3.5)\*4.4 (2.0, 7.2)1.1 (0.6, 1.7)\*5.4 (3.5, 16.4)2.8 (1.3, 3.5)\*Relaxation rate (min)N/AN/A5.0 (4.7, 9.1)2.4 (0.7, 4.5)\*N/AN/AMedian data with first and third quartiles in parenthesisAUC for spontaneous contractions obtained over the last 20 min of the control period, whereas for KCl it was obtained from one contraction developed in response to 2 min exposure to high KCl\**p* \< 0.05N/A, not available

**The effect of oxytocin** Oxytocin was added to the perfusate after spontaneous contractions had been established. In non-diabetic patients (*n* = 7), it produced a marked increase in uterine contractility and underlying Ca^2+^ signals (Fig. [1b](#Fig1){ref-type="fig"}). Thus the amplitude and AUC of both contractions and Ca^2+^ showed significant increases; when compared with spontaneous contractions (100%), the mean amplitude and contraction AUC were 184 ± 15% and 337 ± 46% au, respectively. In diabetic patients (*n* = 6), oxytocin also produced a significant increase in both, which were not significantly different from that found in control group, 219 ± 26% and 332 ± 83% respectively (Fig. [1d](#Fig1){ref-type="fig"}). However, in the diabetic samples contractility, even when stimulated with oxytocin, remained significantly reduced when compared with oxytocin stimulation in non-diabetic patients.

**High K solution** As a significant decrease in Ca^2+^ transient amplitude and duration was found in uteruses from diabetic patients, we investigated if this was due to a lack of activation of the L-type Ca^2+^ channels by using high K^+^ depolarisation to open calcium channels.As can be seen (Fig. [1c](#Fig1){ref-type="fig"}, *n* = 14 in each group), 40 mmol/l K^+^ produced a large increase in force, which plateaus and then declines. A similar response pattern occurred in both types of biopsy but the amplitude was significantly greater in non-diabetic 3.0 mN (1.3, 4.5) compared with diabetic samples 1.5 (0.8, 3.0). There were also significant differences in the duration and AUC (Table [4](#Tab4){ref-type="table"}).

**Ca channels** Immunohistochemical studies revealed the α~1C~ subunit in myocyte membranes (Fig. [2a](#Fig2){ref-type="fig"}, non-diabetic myometrium *n* = 10, diabetic myometrium, *n* = 10). Figure [2a](#Fig2){ref-type="fig"} (bottom) shows controls and negative control with antibody-peptide adsorption. Relative abundance of L-type calcium channel immunoreactivity was reduced in diabetic samples compared with age-matched myometrial samples from non-diabetic patients. Western blotting revealed a ∼220 kDa band, the predicted molecular weight of L-type calcium channels (*n* = 9 non-diabetic and ten diabetic patients, Fig. [2b](#Fig2){ref-type="fig"}). Analysis of signal intensity revealed a small but significant decrease in L-type calcium channel expression in diabetic (63.64 ± 3.694%) compared with non-diabetic myometrium (76.85 ± 3.911%) when expressed as a percentage of GAPDH internal control expression.Fig. 2Uterine histology and Ca channels. **a** Tissue distribution of L-type calcium channels. Immunohistochemical localisation of L-type calcium channels in non-diabetic and diabetic myometrium with positive and negative controls underneath. Scale bar, 50 μm. **b** Quantification of L-type calcium channel expression. Densitometric western blot quantification of L-type calcium channels in non-diabetic and diabetic patients. **c** Effect of Bay K-8644 stimulation. Simultaneous measurements of force and Ca (Indo-1) in myometrium from non-diabetic and diabetic patients during spontaneous activity and with application of 1 μmol/l of the Ca channel agonist, Bay K-8644. **d** and **e** Myometrial histology. **d** H&E. **e** Masson's Trichrome-stained uterine sections from non-diabetic and diabetic patients. Scale bar, 50 μm. Significant difference, \**p* \< 0.05As can be seen in Figs [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}, the changes in contractility in both non-diabetic and diabetic myometrium, whether occurring spontaneously or in response to oxytocin or high K^+^ solutions, were a reflection of the changes in intracellular \[Ca^2+^\], as recorded by Indo-1 fluorescence. Table [2](#Tab2){ref-type="table"} gives the time to peak amplitude, duration at half-height, relaxation time and AUC of the Ca^2+^ transients. All apart from time to peak were significantly reduced in the diabetic samples. To further investigate the mechanism underlying the transient fall in Ca^2+^ in diabetic samples, we used the agonist BAY K-8644, which increases the open probability of L-type Ca^2+^ channels. Figure [2c](#Fig2){ref-type="fig"} shows the effect of the L-type Ca^2+^ channel opener Bay K8644 (1 μmol/l). Application of BAY K-8644 produced a large stimulation of Ca^2+^ entry and augmentation of force in both diabetic (*n* = 5) and non-diabetic (*n* = 5) samples. Baseline Ca^2+^ and force were also elevated. As can be seen in Fig. [2c](#Fig2){ref-type="fig"}, however, diabetic samples showed significantly smaller increments in AUC for both force and Ca^2+^, compared with control values of 100%: in diabetic patients their increases were 194 ± 36% and 124 ± 20%, respectively, whereas in non-diabetic patients these values were 353 ± 48% and 224 ± 36%.

**Histology** Light microscopic examination of H&E-stained myometrial sections from ten diabetic and ten non-diabetic patients were examined. There were no differences in myometrial appearance from diabetic samples; muscle bundle size, organisation and separation were all normal (Fig. [2d](#Fig2){ref-type="fig"}). The percentage muscle for each section was calculated and the overall average taken for both groups. There was a small but significant (*p* \< 0.001) reduction in the muscle content of the diabetic compared with the non-diabetic sections (79.9 ± 1.1% vs 86.7 ± 1.2%) respectively. Masson's Trichrome stained sections were used to investigate if this difference in muscle content was due to alterations in collagen deposition. There was a small but significant (*p* \< 0.02) reduction in the muscle content of the diabetic compared with the non-diabetic sections (44.8 ± 2.2% vs 54.1 ± 1.3%) respectively (Fig. [2e](#Fig2){ref-type="fig"}). Analysis of the collagen deposition showed a non-significant change in the collagen deposition in the diabetic group (22.1 ± 1.9% vs 26.2 ± 2.9%).

**Effect of diet versus insulin diabetic control** The majority of patients were using insulin to control their blood glucose levels, but nine gestational diabetic patients used dietary control alone. We therefore analysed them separately and compared the data to those for patients taking insulin. There were no significant differences between groups (data not shown).

Discussion {#Sec4}
==========

By studying a large number of uterine biopsies from pregnant diabetic patients we have found that when compared with matched non-diabetic patients, contractility is significantly reduced. Analysis of the diabetic patients showed that these findings held even when insulin-treated were compared with diet-controlled gestational diabetic patients. Contractility was poorer in the diabetic samples whether arising spontaneously, with oxytocin or high K^+^; calcium channel expression and signalling were reduced and are likely to account for the reduction in contractility. The reductions in Ca signals are consistent with the reduced Ca^2+^ channel expression and function in myometria from diabetic patients. The small but significant decrease in myometrial mass will also contribute to the decreased contractility. Our data suggest that in labour, myometrial activity will be poorer in diabetic patients and will lead to an increase risk of CS even when controlling for other factors such as obesity and hypertension.

**Effects on contractions** There are few studies investigating myometrial contractility in diabetes with which to compare our data. Force in isolated uteruses from diabetic rats was decreased compared with control rats \[[@CR22]\], consistent with our data on human myometrium. An earlier report on human myometrium from diabetic patients noted that the stability of contractions, as measured by their decrement within 1 h, was reduced in diabetic patients, that is, force was reduced faster \[[@CR25]\]. However, although we found the amplitude and duration of contractions to be reduced in diabetic patients, this activity was well maintained for several hours. Unfortunately, Kaya et al. \[[@CR25]\] did not compare contraction amplitude or any other parameters of contraction. Thus, our study is the first to document the changes in contractility in human myometria from diabetic patients, and it reveals that the spontaneous contractions and their accompanying Ca transients were significantly lower in diabetic patients compared with non-diabetic patients. The amplitude and duration were significantly decreased, so much so that the AUC was only half that of the non-diabetic patients.No previous work has investigated the effect of oxytocin on human diabetic myometrium. A previous study on myometria from diabetic rats reported that oxytocin stimulation was similar to that in control rats \[[@CR22]\], whereas McMurtrie et al. \[[@CR21]\] found maximal responses reduced. We found that oxytocin increased myometrial force and calcium transients in non-diabetic and diabetic patients about equally. Thus, it appears that the diabetic uterus can respond to oxytocin, making it unlikely that oxytocin receptors have been downregulated or that the signalling pathways elicited by it are impaired. In other smooth muscles mainly studied in diabetic animals, both increased and decreased agonist responses are reported (e.g. \[[@CR34]--[@CR36]\]) and no consistent mechanism has been identified.Our data with high K^+^ stimulation showed a significant decrease in amplitude of force and Ca rise in diabetic samples. There is no consistency in the reported effects of high K+ on other smooth muscle preparations from diabetic tissues, with similar findings to ours reported by some \[[@CR36]--[@CR38]\], but no change or increase by others \[[@CR20], [@CR39]\]. Our data are consistent with those of Wang et al. \[[@CR40]\], who also found decreased L-type Ca^2+^ current density discussed below, but our data could also be due to decreased channel expression and altered channel kinetics.

**Histology** The differences in force output in the uterine biopsies from patients with diabetic pregnancy may be due to structural changes. No obvious differences in cellular abundance or orientation were seen at the light microscopic level, but there was a difference in the amount of muscle present. There have been no other histological studies of diabetic human myometrium and only one electron microscopic study performed in rats \[[@CR21]\]. These authors saw no differences in nuclei or mitochondria between streptozotocin-treated and control rats but noted, with no quantification or elaboration, that the number and cellular orientation of myofilaments in euglycaemic animals 'appeared different'.

**Ca signalling** Myometrial contractility is dependent on calcium influx via voltage-gated channels, and hence on membrane potential \[[@CR41], [@CR42]\]. Changes in myosin phosphorylation and Ca sensitivity with diabetes have been reported in a study of bladder smooth muscle, but changes in Ca sensitisation are not a prominent feature of myometrium \[[@CR43]\]. We found that calcium transient amplitude and duration are less in diabetic compared with non-diabetic samples. Therefore, a defect in channel activation, function or expression may occur as a consequence of the diabetic environment. Despite the large number of studies from diabetic animals reporting impaired contractility, few studies have investigated the underlying mechanisms or measured intracellular Ca^2+^.Studies of resting membrane potential show no significant changes with diabetes \[[@CR36], [@CR44], [@CR45]\], suggesting that K^+^ channel activity is unaltered. Reduction in release of Ca^2+^ from the sarcoplasmic reticulum, Ca^2+^ sparks, and activators of Ca-activated K channel (BK) channels was reported in coronary micro-vessels with diabetes in pigs \[[@CR46]\]. However, such mechanisms are unlikely to play a role in the uterus as Ca^2+^ sparks are not present \[[@CR47]\]. Consistent with no change in membrane potential, we found no difference in the resting Indo-1 ratios, suggesting no change in resting \[Ca\], in agreement with data on bladder muscle cells \[[@CR48]\].Stimulation of diabetic uterine tissue with oxytocin and high K produced large rises in Ca, indicating that these pathways to Ca^2+^ mobilisation were functional. Thus, our data do not support a role for alteration in the initiation of Ca^2+^ signalling with diabetes mellitus but rather point to changes in the expression or regulation of L-type Ca^2+^ channels, perhaps as a consequence of glycosylation of residues. There is evidence to support this in our data and other studies. Wang et al. \[[@CR40]\] found a decrease in current density, but no change in cell capacitance, studying rat tail arteries. In cardiac muscles, diabetes is associated with impairment of contraction, and reduced intracellular Ca \[[@CR49], [@CR50]\], caused by a reduction in the Ca^2+^ current. This, in turn, has been attributed to a decrease in Ca channel function or expression \[[@CR49], [@CR50]\]. Wang et al. also found a stimulatory effect of BAY K-8644 in diabetic preparations, as we did in the uterus, suggesting that the number of Ca^2+^ channels may be reduced, as it could improve Ca^2+^ signalling in diabetic myometrium but not restore signals to the level found in non-diabetic samples. A similar argument can be made to explain our high K^+^ data.In summary, our data point to both histological and cellular changes occurring in diabetic patients that compound to reduce contractility, and Ca^2+^ signalling. What the mechanistic trigger for this is remains to be investigated in further studies. In particular, the role of changes in insulin receptors and protein glycosylation should be examined.

**The impact of diabetes on labour outcome** Studies worldwide have shown a much higher CS rate in diabetic compared with non-diabetic patients \[[@CR2]--[@CR4]\]. Although fetal distress, macrosomia and obesity may contribute to this increased emergency CS rate, prolonged labour and failed induction of labour accounted for 51% of emergency CS \[[@CR6]\]. Therefore, poor myometrial contractility has been suggested as an important factor in diabetic pregnancies, and our data support this conclusion. Before discussing the implications further, we will first discuss some aspects of our patient data.Our data are based on 40 diabetic myometrial biopsies. With any study of human disease there will be confounding factors and complications, and in diabetes factors such as obesity can complicate interpretation. However, as shown, there were no significant differences in median age, parity, BMI or birthweight between our groups and our data remained significant when confounders were analysed. We also found that the difference held when method of control of glucose was examined; contraction was reduced in both the insulin patients and those exercising dietary control. Thus, we conclude that it is the diabetic environment that is responsible for the reductions in force we have found.This impaired contractility, if translated in vivo would lead to poor labour contractions and failure to progress. This, in turn, would be an indication for CS and thus our findings help explain the increased rate of CS in diabetic patients. As we have shown, this impairment persists even with oxytocin stimulation and may help explain why progress in labour may remain poor in diabetic patients, even when oxytocin is administered. Diabetic patients also experience a higher rate of failed labour induction than non-diabetic patients \[[@CR6]\]. Although the reasons for this are unknown, we suggest that the poorer contractility in diabetic patients will play a role, although other endocrinological changes such as oestrogen levels cannot be excluded. Nationally and internationally, clinical management of diabetic labours (induction of labour or oxytocin augmentation) is non-specific, that is exactly the same as in non-diabetic patients. Dosages of oxytocin are only altered depending on parity or a history of a previous Caesarean section. Pursuant to our extensive laboratory data, we suggest that all diabetic labours should be considered a unique entity and require a different approach compared with non-diabetic patients. We hypothesise that a higher dosage increment or a longer duration of oxytocin may be required in diabetic labours to counteract the inherent poor uterine contractility, although any adverse outcomes of using higher dosages of oxytocin would need to be considered. We are aware of an ongoing study (HOLDS, [www.holds.bham.ac.uk](http://www.holds.bham.ac.uk)) that is examining the role of higher doses of oxytocin for augmentation in non-diabetic patients. Such augmentation measures may reduce the number of failed inductions as well as the number of women having poor progress in labour.In conclusion, our data give insight into the effects of diabetes on human myometrium. This is the first study to investigate contractile activity---including that induced by oxytocin. Our findings that, irrespective of the mechanism generating contractions, there is a deficit in force compared with non-diabetic patients adds to the clinical data suggesting that poor myometrial contractility may be an important factor in diabetic pregnancies.
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